ORGO Q2 2025 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$101M-22.6% YoY

Gross Profit

$73M72.6% margin

Operating Income

-$13M-12.5% margin

Net Income

-$9M-9.3% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+16.2%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$37M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$461M

Total Liabilities

$100M

Stockholders' Equity

$361M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$130M	-22.6%
Gross Profit	$73M	$101M	-27.6%
Operating Income	-$13M	-$14M	+9.5%
Net Income	-$9M	-$17M	+44.9%

Revenue Segments

Product

$101M100%

Grant

$226,0000%